In the older people trials actually enroll, yes. A post hoc analysis pooled safety across seven tirzepatide trials and found no clinically meaningful difference against placebo in adults aged 65 and over for gastrointestinal tolerability, falls, fractures, depression, pancreatitis, or renal, hepatic, gallbladder and biliary events [1]. Across 17,604 SELECT participants sorted by a 31-item frailty index, the cardiovascular benefit did not differ by frailty, and the odds of improving a frailty category by week 104 were 2.46 times higher on semaglutide than on placebo [2]. Every one of those people had qualified for a phase 3 trial, which excludes most of what makes prescribing to an older patient difficult in the first place.
Age is one of the commonest reasons a clinician hesitates over these drugs, and the evidence behind that hesitation has been thin in both directions. A post hoc analysis worked through the SURMOUNT trials, including the three-year extension, along with SURMOUNT-OSA and SUMMIT, comparing participants aged 65 and over against those under 65 [1]. The related question of whether frailty changes that answer is taken up in the frailty analysis.
The efficacy conclusion is that older participants did about as well as younger ones on weight, on cardiometabolic risk factors and on quality of life. No pooled number is attached to that: efficacy was analyzed study by study at whatever timepoint each trial used, so “broadly comparable” is the finding and there is no single figure to quote.
The safety list is more useful than the summary, because it shows what was actually examined. Gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and renal, hepatic, gallbladder and biliary adverse events were each checked in the older group against placebo, and none showed a clinically meaningful difference. Falls and fractures appearing on that list matters, since those are the specific fears that attach to rapid weight loss in older people.
What frailty did, in the largest sample that measured it
A secondary analysis of SELECT built a 31-item frailty index across 17,604 adults with established cardiovascular disease and no diabetes [2]. Thirty-one percent scored at or below 0.210, 47% between 0.211 and 0.310, and 22% at 0.311 or above. The treatment effect on major cardiovascular events did not track frailty, with the test for interaction at P = .09.
Two results there carry more weight than any subgroup slice. Benefit on the EQ-5D-5L quality of life score was larger at higher frailty, interaction P = .02. And frailty was not fixed: participants on semaglutide were more likely to improve a frailty category by week 104 (OR 2.46, 95% CI 1.80 to 3.37) and less likely to worsen one (OR 0.47, 95% CI 0.34 to 0.65).
The tolerability result runs against the intuition that drives the caution. Adverse events leading to permanent discontinuation were relatively lower, not higher, among participants with greater baseline frailty (P < .001 for interaction). The full reading, including why the three subgroup hazard ratios should not be compared against each other, is in the SELECT frailty analysis.
The one trial where frailty changed the answer
A prespecified pooled analysis of the two STEP-HFpEF trials sorted 1,145 participants by a cumulative-deficit frailty index, and most of them were frail: 692 people, 60.4%, fell in the most-frail group and only 110 were nonfrail [3]. Weight loss was similar across every stratum, with a P value for interaction of 0.38.
The symptom benefit was not similar at all. In the most frail the mean difference against placebo at 52 weeks was 11.0 points, 95% CI 8.1 to 13.8, with P for interaction below 0.001. In the nonfrail group it was −1.5, on an interval from −8.4 to 5.4, which demonstrates nothing in either direction on 110 people. The people who improved most were the ones in the worst shape at the start, which is set out in the heart failure frailty analysis.
What none of these analyses measured
Body composition over years, in an age group already losing muscle without any drug. Trials measured weight, and sarcopenia develops across years rather than appearing as a listed adverse event. The best-controlled body composition figure available comes from 101 adults over 24 weeks, where semaglutide changed lean body mass by −2.5 kg against placebo on an interval running from −6.6 to 1.6 [4].
An interval that wide includes no change at all, and some of what a scan records as lost lean mass is fluid rather than muscle. Nothing there supports a claim that these drugs spare muscle, and nothing supports a claim that they destroy it. What it supports is measuring, and the full state of that question is in what these drugs do to muscle and in what comes back afterward.
Where the evidence stops
That boundary is where observational data has to take over, with its own weaknesses. A cohort can include the frail and the very old in a way a trial never will, at the cost of never knowing who was chosen for treatment and why. That trade-off is visible in the semaglutide and tirzepatide comparison and in the network meta-analysis of nineteen drugs.
For someone over 65 buying online, the practical gap is not the evidence. It is that an intake form cannot see mobility, cognition or the rest of a medication list, and a reassuring safety list drawn from trial participants should not be read as a complete one. What a seller asks before shipping, and who reviews the answers, is counted in what sellers will not tell you.